ExSAR Corporation, a New Jersey-based company, was founded in 1997 with the purpose of utilizing hydrogen/deuterium (H/D) exchange mass spectrometry technology to identify lead candidates for therapeutics aimed at diseases characterized by misfolding proteins. The technology has enabled ExSAR to identify and begin development of therapeutic agents for diseases that include Late-Onset Tay-Sachs, Gaucher, Sandhoff, ALS and Parkinson’s. The potential of H/D-Exchange technology as a means to streamline lead molecule identification is unmistakable.
Today, ExSAR provides access to its well-respected proprietary methods for H/D-Exchange analysis on a fee-for-service basis. Our core technology has been used by most Top 10 pharma and biopharma companies to provide answers to their questions surrounding their lead candidates and therapeutic agents.
At ExSAR, our focus is advancing the identification and development of therapeutic agents through H/D-Exchange mass spectrometry technology. ExSAR’s goal is to become the industry’s number one source for H/D-Exchange analysis worldwide.